vaxcyte inc - PCVX
PCVX
Close Chg Chg %
47.81 -0.16 -0.33%
Closed Market
47.65
-0.16 (0.33%)
Volume: 630.61K
Last Updated:
Dec 24, 2025, 1:00 PM EDT
Company Overview: vaxcyte inc - PCVX
PCVX Key Data
| Open $47.56 | Day Range 47.05 - 48.31 |
| 52 Week Range 27.66 - 93.77 | Market Cap $6.26B |
| Shares Outstanding 130.91M | Public Float 126.95M |
| Beta 1.28 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$4.92 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.49M |
PCVX Performance
| 1 Week | 2.65% | ||
| 1 Month | -3.95% | ||
| 3 Months | 40.23% | ||
| 1 Year | -41.15% | ||
| 5 Years | 70.42% |
PCVX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About vaxcyte inc - PCVX
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
PCVX At a Glance
Vaxcyte, Inc.
825 Industrial Road
San Carlos, California 94070
| Phone | 1-650-837-0111 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -463,927,000.00 | |
| Sector | Health Technology | Employees | 414 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
PCVX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.093 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.009 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.009 |
PCVX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,120,596.618 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PCVX Liquidity
| Current Ratio | 12.755 |
| Quick Ratio | 12.755 |
| Cash Ratio | 12.464 |
PCVX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -18.778 |
| Return on Equity | -20.409 |
| Return on Total Capital | -13.738 |
| Return on Invested Capital | -20.024 |
PCVX Capital Structure
| Total Debt to Total Equity | 2.151 |
| Total Debt to Total Capital | 2.106 |
| Total Debt to Total Assets | 2.013 |
| Long-Term Debt to Equity | 1.973 |
| Long-Term Debt to Total Capital | 1.931 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Vaxcyte Inc - PCVX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 1.80M | 9.20M | 10.17M | 15.85M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.80M | 9.20M | 10.17M | 15.85M | |
Depreciation
| 1.80M | 9.20M | 10.17M | 15.85M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +28.11% | +410.89% | +10.60% | +55.79% | |
Gross Income
| (1.80M) | (9.20M) | (10.17M) | (15.85M) | |
Gross Income Growth
| -28.11% | -410.89% | -10.60% | -55.79% | |
Gross Profit Margin
| - | - | - | - | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 101.87M | 200.06M | 382.87M | 553.70M | |
Research & Development
| 78.41M | 169.45M | 332.34M | 476.64M | |
Other SG&A
| 23.46M | 30.61M | 50.53M | 77.06M | |
SGA Growth
| +15.53% | +96.39% | +91.37% | +44.62% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 23.00M | 75.00M | - |
EBIT after Unusual Expense
| (103.67M) | (232.26M) | (468.04M) | (569.55M) | |
Non Operating Income/Expense
| 3.59M | 8.77M | 65.78M | 105.62M | |
Non-Operating Interest Income
| 344.00K | 8.36M | 62.91M | 109.99M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | -100.00% | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (100.08M) | (223.49M) | (402.27M) | (463.93M) | |
Pretax Income Growth
| -12.17% | -123.31% | -80.00% | -15.33% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (100.08M) | (223.49M) | (402.27M) | (463.93M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (100.08M) | (223.49M) | (402.27M) | (463.93M) | |
Net Income Growth
| -12.17% | -123.31% | -80.00% | -15.33% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (100.08M) | (223.49M) | (402.27M) | (463.93M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (100.08M) | (223.49M) | (402.27M) | (463.93M) | |
EPS (Basic)
| -1.9274 | -3.4447 | -4.1403 | -3.8028 | |
EPS (Basic) Growth
| -10.33% | -78.72% | -20.19% | +8.15% | |
Basic Shares Outstanding
| 51.92M | 64.88M | 97.16M | 122.00M | |
EPS (Diluted)
| -1.9274 | -3.4447 | -4.1403 | -3.8028 | |
EPS (Diluted) Growth
| -10.33% | -78.72% | -20.19% | +8.15% | |
Diluted Shares Outstanding
| 51.92M | 64.88M | 97.16M | 122.00M | |
EBITDA
| (101.87M) | (200.06M) | (382.87M) | (553.70M) | |
EBITDA Growth
| -15.53% | -96.39% | -91.37% | -44.62% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 98.00 | |
| Number of Ratings | 10 | Current Quarters Estimate | -1.502 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -5.408 | |
| Last Quarter’s Earnings | -1.56 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.80 | Next Fiscal Year Estimate | -6.152 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 5 | 9 | 10 |
| Mean Estimate | -1.50 | -1.52 | -5.41 | -6.15 |
| High Estimates | -1.17 | -1.15 | -4.50 | -4.16 |
| Low Estimate | -1.90 | -1.96 | -6.44 | -8.41 |
| Coefficient of Variance | -16.90 | -25.43 | -10.21 | -22.99 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Vaxcyte Inc - PCVX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Vaxcyte Inc - PCVX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 11, 2025 | Heath Lukatch Director | 14,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 11, 2025 | Heath Lukatch Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 11, 2025 | Heath Lukatch Director | 14,175 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $21.49 per share | 304,620.75 |
| Apr 11, 2025 | Heath Lukatch Director | 13,175 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16 per share | 210,800.00 |
| Apr 9, 2025 | Andrew L. Guggenhime PRESIDENT AND CFO | 131,950 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $20.93 per share | 2,761,713.50 |
| Apr 9, 2025 | Andrew L. Guggenhime PRESIDENT AND CFO | 121,115 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2025 | Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director | 518,775 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $20.93 per share | 10,857,960.75 |
| Apr 7, 2025 | Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director | 298,360 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2025 | Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director | 186,936 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 7, 2025 | Grant E. Pickering CHIEF EXECUTIVE OFFICER; Director | 514,023 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.35 per share | 2,750,023.05 |
| Feb 20, 2025 | Andrew L. Guggenhime PRESIDENT AND CFO | 246,827 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Andrew L. Guggenhime PRESIDENT AND CFO | 109,491 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.58 per share | 9,260,748.78 |
| Jan 6, 2025 | James Wassil CHIEF OPERATING OFFICER | 213,695 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.42 per share | 517,141.90 |
| Jan 6, 2025 | James Wassil CHIEF OPERATING OFFICER | 212,339 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $82.88 per share | 17,598,656.32 |
| Jan 6, 2025 | James Wassil CHIEF OPERATING OFFICER | 206,856 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.69 per share | 17,311,778.64 |
| Jan 6, 2025 | James Wassil CHIEF OPERATING OFFICER | 205,695 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $84.43 per share | 17,366,828.85 |
| Jan 6, 2025 | James Wassil CHIEF OPERATING OFFICER | 10,638 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |